Clinical Trials & Medical Discoveries The most recent news and results from scientific and medical research, covering all aspects of healthcare, including testing, diagnosis, and treatment. Stay up-to-date on the latest medical discoveries and breakthroughs with announcements of new products to be tested, upcoming clinical trials and studies, and newly published results. Also included are updates regarding funding decisions, company performance, and legal news.

Latest

Dec 11, 2017, 08:20 ET Caris Life Sciences Identifies New Mechanism of Action for an Aptamer with Therapeutic Potential to Treat Non-Hodgkin Lymphoma

Caris Life Sciences®, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, today announced a data...


Dec 11, 2017, 08:10 ET German Federal Ministry of Education and Research to Fund the CytoSorb® Endocarditis REMOVE Trial

CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader using CytoSorb® blood purification to treat deadly...


Dec 11, 2017, 08:00 ET Genomic Health Presents New Data Demonstrating Value of Oncotype DX® to Optimize Breast Cancer Outcomes and Reduce Treatment Burden throughout Disease Continuum

Genomic Health, Inc. (NASDAQ: GHDX) today announced results of 10 studies that reinforce the unmatched value of the Oncotype DX Breast Recurrence...


Dec 11, 2017, 08:00 ET Sophiris Bio Announces Complete Enrollment in Phase 2b Topsalysin Study of Localized Prostate Cancer

Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris") today announced that it has completed enrollment in its Phase 2b study to evaluate...


Dec 11, 2017, 07:05 ET Medigene Collaborates with RXi Pharmaceuticals to Further Sharpen its Therapeutic T cells

RXi Pharmaceuticals Corporation (NASDAQ: RXII) announced today that it has entered into a research collaboration with Medigene AG (MDG1, Frankfurt,...


Dec 11, 2017, 06:45 ET FDA Accepts Biologics License Application (BLA) to Review Galcanezumab for the Prevention of Migraine in Adults

Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has accepted a Biologics License...


Dec 11, 2017, 06:01 ET Eating Yogurt May Help Reduce Chronic Inflammation in Women, New Clinical Trial Reveals

Eating yogurt on a regular basis may help reduce measures of chronic inflammation in women and support a healthy digestive system, researchers from...


Dec 11, 2017, 05:38 ET NeuroVive Reports Promising Progress in its Clinical Project for Genetic Mitochondrial Diseases, KL1333

NeuroVive Pharmaceutical AB(Nasdaq Stockholm: NVP, OTCQX: NEVPF) and Yungjin Pharm today announced that the phase I clinical study in Korea within...


Dec 11, 2017, 02:48 ET Kyowa Hakko Kirin anuncia los resultados de un ensayo clínicos en fase 3 de mogamulizumab (KW-0761) en pacientes con linfoma cutáneo de células T en American Society of Hematology 2017

Kyowa Hakko Kirin Co., Ltd. (Tokio: 4151, director general y consejero delegado: Nobuo Hanai, "Kyowa Hakko Kirin") anunció hoy que los resultados...


Dec 11, 2017, 02:00 ET Kyowa Hakko Kirin communique à l'American Society of Hematology 2017 les résultats de l'étude clinique en phase 3 du mogamulizumab (KW-0761) chez des patients atteints de lymphome cutané à cellules T

Kyowa Hakko Kirin Co., Ltd. (Tokyo : 4151, Nobuo Hanai président-directeur général de « Kyowa Hakko Kirin ») a annoncé aujourd'hui que les...


Dec 11, 2017, 02:00 ET Kyowa Hakko Kirin gibt die Ergebnisse der klinischen Phase-3-Studie mit Mogamulizumab (KW-0761) bei Patienten mit kutanem T-Zell-Lymphom auf American Society of Hematology 2017 bekannt

Die Kyowa Hakko Kirin Co., Ltd. (Tokio: 4151, President und CEO: Nobuo Hanai, "Kyowa Hakko Kirin") gibt heute bekannt, dass die Ergebnisse der...


Dec 11, 2017, 01:23 ET Betalutin® Shows Strong Clinical Profile in Relapsed/refractory Indolent NHL and Follicular Lymphoma

Nordic Nanovector ASA (OSE: NANO) has presented updated results from its LYMRIT 37-01 Phase 1/2 clinical study of Betalutin®...


Dec 10, 2017, 11:40 ET New Data for FDA-Approved CAR T Therapy Show Significant Remission Rates in 42% of Non-Hodgkin Lymphoma Patients

A new article published today in The New England Journal of Medicine shows that 42 percent of diffuse large B cell lymphoma patients treated with...


Dec 10, 2017, 10:47 ET Primary analysis results from Novartis pivotal JULIET trial show Kymriah™ (tisagenlecleucel) sustained complete responses at six months in adults with r/r DLBCL, a difficult-to-treat cancer

Novartis today announced updated results from the JULIET clinical trial demonstrating sustained responses with Kymriah™ (tisagenlecleucel)...


Dec 10, 2017, 10:30 ET CAR T-Cell Therapies Drive Outcomes in Lymphoma, Myeloma

For people with certain types of aggressive, refractory blood cancers, treatment options are woefully limited. But three studies being presented...


Dec 10, 2017, 08:48 ET Targeted Therapies Show Promise for Improving Outcomes Across a Spectrum of Hematologic Malignancies

Four studies being presented today at the 59th American Society of Hematology (ASH) Annual Meeting and Exposition in Atlanta highlight the multiple...


Dec 10, 2017, 08:32 ET The Emirates Pathology Society (EPS): Earlier Diagnoses of Cancer, Better Survival Rates & Improved Quality of Life Through Next-Generation Sequencing (NGS)

The number of variants identified as being associated with cancer risk and progression is rapidly growing. Meanwhile, advances in medical...


Dec 10, 2017, 08:00 ET Blueprint Medicines Announces New Data from Ongoing Phase 1 Clinical Trial of Avapritinib (BLU-285) in Patients with Advanced Systemic Mastocytosis Showing Evidence of Strong Clinical Activity

Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically...


Dec 10, 2017, 08:00 ET PharmaEssentia Announces Favorable Two-year Results of Ropeginterferon Alfa-2b in Polycythemia Vera at the American Society of Hematology (ASH) Annual Meeting 2017

PharmaEssentia USA, a subsidiary of PharmaEssentia Corporation (Taipei Exchange: 6446), today announced the latest follow-up results of...


Dec 09, 2017, 14:00 ET Immunotherapy Drug for Rheumatoid Arthritis Nearly Eliminates Severe Acute Graft-Versus-Host Disease after Hematopoietic Stem Cell Transplant

Results from a phase 2 clinical trial, presented by Seattle Children's Research Institute at the 59th American Society of Hematology (ASH) Annual...